Compare Amgen, Inc. (AMGN) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Snowflake Inc — how do they compare? Amgen, Inc. trades at $415.49 (market cap $224.14B), while Snowflake Inc trades at $337.74 (market cap $116.01B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays a 2.43% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| AMGN | SNOW | |
|---|---|---|
Market Cap | $224.14B | $116.01B |
Sector | Health | Technology |
52-Week High | $417.20 | $334.70 |
52-Week Low | $271.18 | $121.11 |
Enterprise Value | $267.45B | $115.82B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Snowflake trades at $339.00, up 1.28% with bullish technical signals and strong analyst support (81% buy ratings). The company shows impressive revenue growth from $1.2B in 2022 to $3.6B in 2025, though remains unprofitable with a -23.79% net margin. Recent earnings beats and AI platform expansions drive optimism, but premium valuation at 22.66x P/S ratio presents risk.
Outlook remains positive with AI data cloud leadership and 30% revenue growth guidance, but investors face valuation concerns and persistent losses. Key catalysts include Q2 2026 earnings on September 2nd and enterprise AI adoption trends. The stock trades near resistance at $341 with consensus price target of $302.18 suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
